Insulin Pump Therapy Guidelines
Recommended Insulin Types for Pumps
- The American Diabetes Association recommends rapid-acting insulin analogs, such as insulin lispro, as the preferred insulin for continuous subcutaneous insulin infusion (CSII) pumps, due to their confirmed stability in pump systems 1, 2
- Rapid-acting analogs (lispro, aspart, glulisine) are the standard choice for insulin pumps because of their quick onset, early peak, and short duration, allowing them to mimic physiologic insulin secretion when delivered continuously 5
- Short-acting regular human insulin can be used in insulin pumps, but is less optimal, as controlled trials have demonstrated improved postprandial glucose control with rapid-acting analogs compared to regular insulin when delivered by CSII 1, 2
Insulin Pump Mechanism and Safety Considerations
- The pump delivers approximately 50% of total daily insulin as continuous basal infusion throughout the day and 50% as meal boluses, requiring insulin that can be safely administered in small, frequent doses 24 hours per day 6
- Long-acting insulins (glargine, detemir, degludec) are never used in pumps because they are specifically designed for once or twice daily injection, not continuous infusion 6
- The pump itself provides the "basal" coverage through continuous delivery of rapid-acting insulin, eliminating the need for separate long-acting insulin formulations 7
- Undetected interruptions in insulin delivery may result in ketotic episodes more quickly with CSII compared to multiple daily injection regimens that include long-acting insulin 2, 3
Critical Safety Consideration
- Always carry backup rapid-acting insulin syringes or pens in case of pump failure, as pump malfunction can lead to rapid development of ketoacidosis within hours—a life-threatening emergency 6